The common early treatment options for breast cancer are generally divided into conventional chemotherapy (Adriamycin, cyclophosphamide, paclitaxel, and docetaxel), endocrine therapy (tamoxifen, letrozole, anastrozole, and exemestane), ERBB-targeted therapy (trastuzumab and pertuzumab), and combination treatment methods according to the pathological and molecular classification of breast cancer [2]. This evidence concerns the gene EGFR and breast carcinoma.